Posts Tagged ‘BioNTech’
3 small-dose COVID vaccine for children 6 mos-5 yrs from Pfizer/BioNTech
Pfizer and BioNTech today announced topline safety, immunogenicity and vaccine efficacy data from a Phase 2/3 trial evaluating a third 3-µg dose of the Pfizer-BioNTech COVID-19 Vaccine in children 6 months to under 5 years of age. Following a third dose in this age group, the vaccine was found to elicit a strong immune response,…
Read MoreEmergency approval expected for 4th Pfizer shot for those over 65
Pfizer and BioNTech Submit for U.S. Emergency Use Authorization of an Additional Booster Dose of their COVID-19 Vaccine for Older Adults Pfizer and BioNTech today announced the companies have submitted an application to the U.S. Food and Drug Administration (FDA) for Emergency Use Authorization (EUA) of an additional booster dose adults 65 years of age…
Read MoreCOVID-19 vaccine for children 6 months to 5 coming as FDA asks Pfizer and BioNTech to seek approval
Pfizer and BioNTech Initiate Rolling Submission for Emergency Use Authorization of Their COVID-19 Vaccine in Children 6 Months Through 4 Years of Age Following Request From U.S. FDA Once approval is received, this immunization will take its place among 16 others children are given, some required for attendance in school. With pediatric COVID-19 cases surpassing…
Read MorePfizer-BioNTech announce positive results of COVID vaccine with children, 5-11. Seeking emergency approval.
In an early morning press release by Pfizer, positive results of the COVID vaccine on children, ages 5 to 11 were reported – emergency approval will be sought by the FDA. Vaccinations could proceed by the end of September, to the end of October. Results are the first from a pivotal trial of any COVID-19…
Read More